Addex Therapeutics (ADXN.SW) Stock Price
Addex Therapeutics Price
Revenue at Addex Therapeutics has contracted by 16.0% per year over the past 19 years to 173,000.00 CHF. For Addex Therapeutics, the net margin of -3,889.6% is down versus -528.6% a few years ago.
Addex Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Addex Therapeutics business model & stock analysis
Frequently asked questions about Addex Therapeutics
The business model of Addex Therapeutics Ltd revolves around developing novel oral small molecules for diseases that are currently not well-treated or have a significant unmet medical need. They focus on targeting specific proteins in the central nervous system (CNS) to address therapeutic gaps within neurological disorders and addiction-related diseases. Addex Therapeutics utilizes its proprietary drug discovery platform, allosteric modulation technology, to create innovative therapies. By leveraging their expertise, Addex Therapeutics aims to bring forth effective and safe treatment options to improve patients' lives and generate value for their shareholders.
Addex Therapeutics Ltd is primarily active in the pharmaceutical industry.
The main competitors of Addex Therapeutics Ltd in the market are other biopharmaceutical companies involved in the development and commercialization of novel therapies and treatments targeting similar disease areas. Some key competitors include AbbVie Inc., Alkermes plc, Eli Lilly and Company, and Johnson & Johnson.
Addex Therapeutics Ltd is a biopharmaceutical company with a rich history and background in the field of neuroscience. Founded in 2002, Addex has constantly been working towards the development of innovative therapeutic solutions for diseases such as Parkinson's and Schizophrenia. The company has a strong focus on modulating specific receptors in the brain to target and treat these conditions. With a dedicated team of scientists and researchers, Addex Therapeutics has made significant advancements in drug discovery and has several promising compounds in its pipeline. The company's commitment to improving the lives of patients and its relentless pursuit of groundbreaking therapies has positioned Addex as a leading player in the biopharmaceutical industry.
Addex Therapeutics Ltd has achieved significant milestones in its industry. The company successfully developed and advanced its allosteric modulator drugs, targeting various diseases such as Parkinson's disease and schizophrenia. Addex Therapeutics also achieved notable progress in its clinical development programs, conducting successful Phase II trials for its lead candidate, dipraglurant, in Parkinson's disease levodopa-induced dyskinesia. The company has further strengthened its position through collaborations with industry-leading partners to expedite the development and commercialization of its innovative therapies. With its commitment to scientific excellence and strong pipeline, Addex Therapeutics Ltd continues to make remarkable strides in the field of allosteric modulation for the benefit of patients and investors.
Addex Therapeutics Ltd is primarily present in multiple countries and regions worldwide. The company has a global presence with a focus on key markets such as the United States, Europe, and Asia. By expanding its reach across these regions, Addex Therapeutics Ltd aims to maximize its market potential and cater to a diverse range of customers. With its presence in multiple countries and regions, Addex Therapeutics Ltd is well-positioned to capitalize on emerging opportunities and strengthen its position as a leading player in the pharmaceutical industry.
Addex Therapeutics Ltd represents a set of core values and a corporate philosophy that guide its operations. The company is committed to scientific excellence, innovation, and patient-centricity in the field of drug discovery and development. Addex Therapeutics strives to improve the lives of patients by developing novel oral small molecules targeting specific biological pathways. With a focus on therapeutic areas such as neurology and immunology, the company aims to deliver innovative solutions to unmet medical needs. By fostering collaboration and leveraging its expertise, Addex Therapeutics is dedicated to advancing the frontiers of medicine and bringing transformative therapies to patients worldwide.
9 analysts currently rate the Addex Therapeutics stock: 0 recommend buying, 2 holding and 7 selling. For 2026, analysts expect Addex Therapeutics to generate revenue of 1.50 M CHF and earnings per share of -0.03 CHF.
Converted at the current exchange rate, the Addex Therapeutics share trades at 0.02 EUR (0.02 CHF).
The Addex Therapeutics share (ADXN.SW) is listed on 4 stock exchanges, including: London (0QNV.L), SIX (Zürich) (ADXN.SW), Frankfurt (APE.F), München (APE.MU).
Addex Therapeutics Ltd is a biopharmaceutical company specialized in the development of novel orally available drugs for the treatment of central nervous system diseases, as well as inflammatory and metabolic diseases. The company has developed a unique drug design and screening platform system focusing on allosteric modulators to selectively and effectively develop drugs. Addex Therapeutics operates in three main areas: clinical development programs, preclinical development programs, and partnerships with third parties. In the clinical development programs, Addex Therapeutics has various drug candidates in clinical development or near the start of clinical trials. The company works closely with contract research organizations to conduct these studies and ensure the safety and efficacy of the drug candidates. Addex Therapeutics' clinical development programs include the following drug classes: - ADX10059: A calcium channel modulator that offers an alternative therapy for the treatment of chronic migraine and gastroesophageal reflux disease. - ADX71149: A GABAB receptor modulator that represents a potential treatment option for schizophrenia and alcoholism. - ADX71441: A G-protein coupled receptor modulator that represents a potential treatment option for anxiety disorders. In the preclinical development programs, Addex Therapeutics is working on the development of drug candidates in the earliest phase of the development process. These drug candidates are still in early research and are being tested in vitro and in vivo to determine their potential for further development in later research stages, considering safety and efficacy. Addex Therapeutics has a wide range of technologies for drug discovery. The company utilizes various technologies to effectively shape drug design. Allosteric modulation is at the core of Addex Therapeutics' drug design system, allowing the company to selectively target specific targets within cells and tissues that play a role in various diseases. In partnerships with third parties, Addex Therapeutics collaborates with other companies or academic partners to further develop its drug candidates or develop new technologies. Addex Therapeutics has signed several agreements with leading biotech and pharmaceutical companies to expand the use of allosteric modulators. In addition to its drug candidates, Addex Therapeutics also offers drug discovery services. The company provides its customers with access to its technology platform to identify new drug candidates and accelerate drug development. These services are an important part of Addex Therapeutics' business model and contribute to the company's growth and diversification. Overall, Addex Therapeutics has a unique business model based on the development of novel drugs targeting specific targets within cells and tissues. With its technology platform and broad expertise in drug development, the company is able to efficiently and effectively navigate its drug candidates through clinical development. Addex Therapeutics' strategic partnerships and drug discovery services provide additional growth opportunities. Translation provided by a language model trained on a mixture of professional translations and publicly available data.
The expected revenue of Addex Therapeutics is 1.50 M CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Addex Therapeutics is -3.92 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Addex Therapeutics is currently -0.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Addex Therapeutics stock.
The price-to-sales ratio (P/S) of Addex Therapeutics is currently 2.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Addex Therapeutics stock.
The Eulerpool Quality Score for Addex Therapeutics is 3/10.
The ISIN of Addex Therapeutics is CH0029850754. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Addex Therapeutics is A0MSH6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Addex Therapeutics is ADXN.SW. The ticker symbol is used to trade Addex Therapeutics shares on the stock exchange.
Addex Therapeutics stock
Addex Therapeutics Peer Group
Addex Therapeutics Ticker
Addex Therapeutics FIGI
All fundamentals and in-depth analysis of Addex Therapeutics
Our stock analysis for Addex Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Addex Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.